Corcept Therapeutics Incorporated - Common Stock (NQ:CORT)

42.06 +1.75 (+4.35%)

Streaming Delayed Price Updated: 11:37 AM EDT, Apr 1, 2026 Add to My Watchlist

Price and Volume

Volume	371,932
Open	40.61
Bid (Size)	42.04 (500)
Ask (Size)	42.10 (200)
Prev. Close	40.31
Today's Range	40.60 - 42.15
52wk Range	28.66 - 117.33
Shares Outstanding	115,926,629
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Corcept Therapeutics Incorporated Securities Fraud Class Action Result of FDA Approval Issues and 50% Stock Decline - Investors may Contact Lewis Kahn, Esq, at Kahn Swick & Foti, LLC

March 31, 2026

From Kahn Swick & Foti, LLC

Via GlobeNewswire

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Corcept Therapeutics Incorporated of Class Action Lawsuit and Upcoming Deadlines – CORT

March 31, 2026

From Pomerantz LLP

Via GlobeNewswire

Performance

YTD	+10.1%	+10.1%
1 Month	+16.9%	+16.9%
3 Month	-40.1%	-40.1%
6 Month	-49.4%	-49.4%
1 Year	-63.2%	-63.2%

More News

Bragar Eagel & Squire, P.C. Urges Navan and Corcept Investors with Large Losses to Contact the Firm Before the Upcoming Lead Plaintiff Deadlines

March 31, 2026

From Bragar Eagel & Squire

Via GlobeNewswire

Corcept Therapeutics Outperforms: How a Surprise FDA Approval Ignited a Late-March Rally

March 31, 2026

Via MarketMinute

Biotech Defies Gravity: Sarepta and Corcept Lead Midday Healthcare Rally Amidst Market Volatility

March 31, 2026

Via MarketMinute

CORT Investors Have Opportunity to Lead Corcept Therapeutics Incorporated Securities Fraud Lawsuit with the Schall Law Firm

March 30, 2026

From Schall Law

Via GlobeNewswire

3 Reasons to Avoid CORT and 1 Stock to Buy Instead

March 30, 2026

Via StockStory

Corcept Presents Data from MOMENTUM Trial at American College of Cardiology Annual Scientific Session

March 28, 2026

From Corcept Therapeutics Incorporated

Via Business Wire

Deadline is April 21, 2026 to Lead in Securities Class Action Against Corcept Therapeutics, Inc. (NASDAQ: CORT) - Contact Kaplan Fox

March 28, 2026

Via NewMediaWire

Deadline is April 21, 2026 to Lead in Securities Class Action Against Corcept Therapeutics, Inc. (NASDAQ: CORT) - Contact Kaplan Fox

March 28, 2026

Via TheNewswire.com

Why Corcept Therapeutics Zoomed Nearly 9% Higher This Week ↗

March 27, 2026

Via The Motley Fool

CORCEPT THERAPEUTICS DEADLINE FOR LEADERSHIP is April 21, 2026 in a Securities Fraud Lawsuit - Investors Encouraged to Contact Kaplan Fox

March 27, 2026

Via NewMediaWire

CORCEPT THERAPEUTICS DEADLINE FOR LEADERSHIP is April 21, 2026 in a Securities Fraud Lawsuit - Investors Encouraged to Contact Kaplan Fox

March 27, 2026

Via TheNewswire.com

ROSEN, NATIONAL INVESTOR COUNSEL, Encourages Corcept Therapeutics Incorporated Investors to Secure Counsel Before Important Deadline in Securities Class Action – CORT

March 26, 2026

From The Rosen Law Firm PA

Via GlobeNewswire

Kaplan Fox Reminds Investors of Corcept Therapeutics, Inc. (NASDAQ: CORT) to a Securities Class Action Deadline - Contact Kaplan Fox Before April 21, 2026

March 26, 2026

Via NewMediaWire

Kaplan Fox Reminds Investors of Corcept Therapeutics, Inc. (NASDAQ: CORT) to a Securities Class Action Deadline - Contact Kaplan Fox Before April 21, 2026

March 26, 2026

Via TheNewswire.com

MarketMinute: Corcept Therapeutics (CORT) Surges 19.66% on Surprise FDA Approval and Oncology Breakthrough

March 26, 2026

Via MarketMinute

The Second Act: A Deep-Dive into Corcept Therapeutics and the FDA Approval of Lifyorli

March 26, 2026

Via Finterra

Corcept Therapeutics Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against Corcept Therapeutics Incorporated - CORT

March 25, 2026

From SkyMedia, LLC

Via GlobeNewswire

Why Investors Strapped a Rocket to Corcept Therapeutics Stock on Wednesday ↗

March 25, 2026

Via The Motley Fool

Wednesday's session: top gainers and losers ↗

March 25, 2026

Via Chartmill

FDA Approves Corcept’s Selective Glucocorticoid Receptor Antagonist Lifyorli™ (relacorilant) Plus Nab-Paclitaxel for Treatment of Patients with Platinum-Resistant Ovarian Cancer

March 25, 2026

From Corcept Therapeutics Incorporated

Via Business Wire

What's Behind The Jump In Corcept Therapeutics Stock? ↗

March 25, 2026

Via Benzinga

Deadline Approaching for Investors of Corcept Therapeutics, Inc. (CORT) - Contact Kaplan Fox Before April 21, 2026

March 25, 2026

Via NewMediaWire

Deadline Approaching for Investors of Corcept Therapeutics, Inc. (CORT) - Contact Kaplan Fox Before April 21, 2026

March 25, 2026

Via TheNewswire.com

Frequently Asked Questions

Is Corcept Therapeutics Incorporated - Common Stock publicly traded?

Yes, Corcept Therapeutics Incorporated - Common Stock is publicly traded.

What exchange does Corcept Therapeutics Incorporated - Common Stock trade on?

Corcept Therapeutics Incorporated - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for Corcept Therapeutics Incorporated - Common Stock?

The ticker symbol for Corcept Therapeutics Incorporated - Common Stock is CORT on the Nasdaq Stock Market

What is the current price of Corcept Therapeutics Incorporated - Common Stock?

The current price of Corcept Therapeutics Incorporated - Common Stock is 42.06

When was Corcept Therapeutics Incorporated - Common Stock last traded?

The last trade of Corcept Therapeutics Incorporated - Common Stock was at 04/01/26 11:37 AM ET

What is the market capitalization of Corcept Therapeutics Incorporated - Common Stock?

The market capitalization of Corcept Therapeutics Incorporated - Common Stock is 4.88B

How many shares of Corcept Therapeutics Incorporated - Common Stock are outstanding?

Corcept Therapeutics Incorporated - Common Stock has 5B shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.